Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Generation of iPSC-derived CD4+ Th1 cells enhancing chimeric antigen receptor-T cell cytotoxicity

ABSTRACT: Generation of iPSC-derived CD4+ Th1 cells enhancing chimeric antigen receptor-T cell cytotoxicity

PROVIDER: PRJNA1289096 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Generation of iPSC-derived CD4+ Th1 cells enhancing chimeric antigen receptor-T cell cytotoxicity

Project description:CD4+ T cells are anticipated to enhance the overall immune response, including the anti-tumor activity of chimeric antigen receptor (CAR)-T cell therapy. In the past, we established a culture system to generate CD8+ T cells from iPS cells (iPSCs); however, it was challenging to generate CD4+ T cells. Drawing inspiration from the observation that adult T cell leukemia (ATL) cells are consistently CD4+ and possess Treg characteristics, we successfully generated CD4+ Treg cells by reprogramming ATL cells into iPSCs and then differentiating them into T cells. Gene expression analysis of this generation system suggested that RUNX3 serves as a key regulator in T cell differentiation within the ex vivo generation system. By knocking out RUNX3, we demonstrated the generation of antigen-specific CD4+ Th1 cells via the iPSC route, thereby enhancing the activity of CD8+ CAR-T cells against GD2-expressing lymphoma. These technologies hold significant promise for contributing to “off-the-shelf” immunotherapies against malignant tumors, including solid tumors.

2025-07-13 | GSE302158 | GEO

Phase separation of chimeric antigen receptor promotes immunological synapse maturation and persistent cytotoxicity

Project description:Phase separation of chimeric antigen receptor promotes immunological synapse maturation and persistent cytotoxicity

| PRJNA1167671 | ENA

Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with Δ133p53α

Project description:Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with Δ133p53α

| PRJNA1043646 | ENA

chimeric antigen receptor T cells with knockout

Project description:chimeric antigen receptor T cells with knockout

| PRJNA727540 | ENA

Coordinate tumor-antigen uptake and dendritic cell activation by chimeric antigen receptors.

Project description:Coordinate tumor-antigen uptake and dendritic cell activation by chimeric antigen receptors.

| PRJNA1244298 | ENA

Epigenetic profiles of chimeric antigen receptor T cells

Project description:Epigenetic profiles of chimeric antigen receptor T cells

| PRJNA916209 | ENA

High affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells

Project description:Regulatory T cells (Tregs) are promising cellular therapies to induce immune tolerance in organ transplantation and autoimmune disease. The success of chimeric antigen receptor (CAR) T-cell therapy for cancer has sparked interest in using CARs to generate antigen-specific Tregs. Here, we compared CAR with endogenous T cell receptor (TCR)/CD28 activation in human Tregs. Strikingly, CAR Tregs displayed increased cytotoxicity and diminished suppression of antigen-presenting cells and effector T (Teff) cells compared with TCR/CD28 activated Tregs. RNA sequencing revealed that CAR Tregs activate Teff cell gene programs. Indeed, CAR Tregs secreted high levels of inflammatory cytokines, with a subset of FOXP3+ CAR Tregs uniquely acquiring CD40L surface expression and producing IFNγ. Interestingly, decreasing CAR antigen affinity reduced Teff cell gene expression and inflammatory cytokine production by CAR Tregs. Our findings showcase the impact of engineered receptor activation on Treg biology and support tailoring CAR constructs to Tregs for maximal therapeutic efficacy.

2024-11-30 | GSE282623 | GEO

Coordinate tumor-antigen uptake and dendritic cell activation by chimeric antigen receptors. [TCR-seq]

Project description:Effective anti-tumor immunity requires dendritic cells (DCs) to internalize, process and present tumor antigens to T cells. Adoptive transfer of DCs loaded ex vivo with tumor antigens has been shown to stimulate anti-tumor immunity in patients with cancer, but clinical responses have been mixed. To address limitations of traditional DC-based therapies, we constructed and functionally screened a panel of chimeric antigen receptors (CARs) optimized for expression and activity in DCs. Through this screening, we identified key functional components that informed the design of an inducible platform centered on an instructive chimeric antigen receptor (iCAR). This platform enables the DCs to (i) recognize a surface molecule present on cancer cells or their extracellular vesicles (EVs), such as GD2 and HER2, thereby promoting the acquisition of tumor-derived material that contains putative tumor antigens; (ii) undergo immunostimulatory activation to prime antigen-specific T cells via both cross-dressing and cross-presentation; and (iii) transactivate the expression of a therapeutic gene (IL-12) in response to antigen uptake. The iCAR converted melanoma-derived EVs from immune-suppressive to stimulatory cues for DCs. Moreover, systemic administration of iCAR-DCs enhanced antigen-specific T cells, expanded low-frequency T cell clonotypes, and delayed tumor growth in immunotherapy-resistant melanoma models without the need for ex vivo antigen loading or cell maturation. iCAR-DCs provide a platform for antigen-agnostic cancer immunotherapy that integrates antigen uptake with programmable DC activation.

2025-12-17 | GSE293373 | GEO

Coordinate tumor-antigen uptake and dendritic cell activation by chimeric antigen receptors. [RNA-seq]

2025-12-17 | GSE293372 | GEO

Coordinate tumor-antigen uptake and dendritic cell activation by chimeric antigen receptors. [RNA-seq]

Project description:Coordinate tumor-antigen uptake and dendritic cell activation by chimeric antigen receptors. [RNA-seq]

| PRJNA1105880 | ENA